In Silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 1, 2014, Pages 52-60

  Handa, Koichi ^a,b   Nakagome, Izumi ^a   Yamaotsu, Noriyuki ^a   Gouda, Hiroaki ^a,c   Hirono, Shuichi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b TOYAMA CHEMICAL CO LTD   (Japan)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

CYP2D6.1; CYP2D6.17; Drug inhibition; Drug drug interactions; Gene polymorphism; MD simulation; MM GB SA

Indexed keywords

COCAINE; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6.1; CYTOCHROME P450 2D6.17; FLUOXETINE; IMIPRAMINE; NORFLUOXETINE; PRINOMASTAT; QUINIDINE; THIORIDAZINE; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; DRUG STRUCTURE; GENETIC POLYMORPHISM; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; REGRESSION ANALYSIS;

COCAINE; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; FLUOXETINE; IMIPRAMINE; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; ORGANIC CHEMICALS; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; QUINIDINE; REGRESSION ANALYSIS; STEREOISOMERISM; THIORIDAZINE;

EID: 84898424172     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-044     Document Type: Article

References (42)

1. Rendic, S.: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev., 34: 83-448 (2002).
2. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
3. Zhou, S. F.: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 48: 689-723 (2009).
4. Kubota, T., Yamaura, Y., Ohkawa, N., Hara, H. and Chiba, K.: Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol., 50: 31-34 (2000).
5. Roh, H. K., Chung, J. Y., Oh, D. Y., Park, C. S., Svensson, J. O., Dahl, M. L. and Bertilsson, L.: Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br. J. Clin. Pharmacol., 52: 265-271 (2001).
6. Liou, Y. H., Lin, C. T., Wu, Y. J. and Wu, L. S.: The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J. Hum. Genet., 51: 857-863 (2006).
7. Ji, L., Pan, S., Wu, J., Marti-Jaun, J. and Hersberger, M.: Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin. Med. J., 115: 1780-1784 (2002).
8. Nakamura, K., Ariyoshi, N., Yokoi, T., Ohgiya, S., Chida, M., Nagashima, K., Inoue, K., Kodama, T., Shimada, N. and Kamataki, T.: CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem. Biophys. Res. Commun., 293: 969-973 (2002).
9. Wan, Y. J., Poland, R. E., Han, G., Konishi, T., Zheng, Y. P., Berman, N. and Lin, K. M.: Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics, 11: 489-499 (2001).
10. Masimirembwa, C., Persson, I., Bertilsson, L., Hasler, J. and Ingelman-Sundberg, M.: A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol., 42: 713-719 (1996).
11. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F. and Ingelman-Sundberg, M.: Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther., 278: 441-446 (1996).
12. Wennerholm, A., Johansson, I., Massele, A. Y., Lande, M., Alm, C., Aden-Abdi, Y., Dahl, M. L., Ingelman-Sundberg, M., Bertilsson, L. and Gustafsson, L. L.: Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics, 9: 707-714 (1999).
13. Panserat, S., Sica, L., Gérard, N., Mathieu, H., Jacqz-Aigrain, E. and Krishnamoorthy, R.: CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br. J. Clin. Pharmacol., 47: 121-124 (1999).
14. Griese, E. U., Asante-Poku, S., Ofori-Adjei, D., Mikus, G. and Eichelbaum, M.: Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics, 9: 715-723 (1999).
15. Wennerholm, A., Dandara, C., Sayi, J., Svensson, J. O., Abdi, Y. A., Ingelman-Sundberg, M., Bertilsson, L., Hasler, J. and Gustafsson, L. L.: The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin. Pharmacol. Ther., 71: 77-88 (2002).
16. Marcucci, K. A., Pearce, R. E., Crespi, C., Steimel, D. T., Leeder, J. S. and Gaedigk, A.: Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab. Dispos., 30: 595-601 (2002).
17. Bogni, A., Monshouwer, M., Moscone, A., Hidestrand, M., Ingelman-Sundberg, M., Hartung, T. and Coecke, S.: Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol. In Vitro, 19: 621-629 (2005).
18. Cai, W. M., Nikoloff, D. M., Pan, R. M., de Leon, J., Fanti, P., Fairchild, M., Koch, W. H. and Wedlund, P. J.: CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J., 6: 343-350 (2006).
19. ICH E5 (R1): Ethnic Factors in the Acceptability of Foreign Clinical Data, February 1998.
20. Liu, J. P. and Chow, S. C.: Bridging studies in clinical development. J. Biopharm. Stat., 12: 359-367 (2002).
21. Matsui, H.: Global drug development based on ICH-E5 guideline. Xenobic Metab. Dispos., 15: 381-385 (2000).
22. Hsiao, C. F., Xu, J. Z. and Liu, J. P.: A two-stage design for bridging studies. J. Biopharm. Stat., 15: 75-83 (2005).
23. Goto, M. and Hamasaki, T.: Practical issues and observations on the use of foreign clinical data in drug development. J. Biopharm. Stat., 12: 369-384 (2002).
24. Hsiao, C. F., Xu, J. Z. and Liu, J. P.: A group sequential approach to evaluation of bridging studies. J. Biopharm. Stat., 13: 793-801 (2003).
25. Naito, C.: Necessity and requirements of bridging studies and their present status in Japan. Int. J. Clin. Pharmacol. Ther., 38: 80-86 (2000).
26. Gupta, S. K.: Implications of ICH-E5: Assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global drug development. Perspect. Clin. Res., 2: 121-123 (2011).
27. Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B. and Li, C.: Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos., 35: 1292-1300 (2007).
28. Akiyoshi, T., Saito, T., Murase, S., Miyazaki, M., Murayama, N., Yamazaki, H., Guengerich, F. P., Nakamura, K., Yamamoto, K. and Ohtani, H.: Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. Drug Metab. Dispos., 39: 724-728 (2011).
29. Oscarson, M., Hidestrand, M., Johansson, I. and Ingelman-Sundberg, M.: A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol., 52: 1034-1040 (1997).
30. Zhou, X., Wang, Y., Or, P. M., Wan, D. C., Kwan, Y. W. and Yeung, J. H.: Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes. Phytomedicine, 19: 648-657 (2012).
31. Mo, S. L., Liu, W. F., Li, C. G., Luo, H. B., Li, R. and Zhou, S. F.: Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to Chinese herbal medicine screening. Curr. Pharm. Biotechnol., 13: 1640-1704 (2011).
32. VandenBrink, B. M., Foti, R. S., Rock, D. A., Wienkers, L. C. and Wahlstrom, J. L.: Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab. Dispos., 40: 47-53 (2012).
33. Mo, S. L., Liu, W. F., Chen, Y., Luo, H. B., Sun, L. B., Chen, X. W., Zhou, Z. W., Sneed, K. B., Li, C. G., Du, Y. M., Liang, J. and Zhou, S. F.: Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin, Baikal Skullcap). Comb. Chem. High Throughput Screen., 15: 36-80 (2012).
34. Schyman, P., Usharani, D., Wang, Y. and Shaik, S.: Brain chemistry: how does P450 catalyze the O-demethylation reaction of 5-methoxytryptamine to yield serotonin? J. Phys. Chem. B, 114: 7078-7089 (2010).
35. Kotsuma, M., Hanzawa, H., Iwata, Y., Takahashi, K. and Tokui, T.: Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab. Dispos., 36: 1938-1943 (2008).
36. Ito, Y., Kondo, H., Goldfarb, P. S. and Lewis, D. F.: Analysis of CYP2D6 substrate interactions by computational methods. J. Mol. Graph. Model., 26: 947-956 (2008).
37. McLaughlin, L. A., Paine, M. J., Kemp, C. A., Maréchal, J. D., Flanagan, J. U., Ward, C. J., Sutcliffe, M. J., Roberts, G. C. and Wolf, C. R.: Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. J. Biol. Chem., 280: 38617-38624 (2005).
38. Bapiro, T. E., Hasler, J. A., Ridderström, M. and Masimirembwa, C. M.: The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem. Pharmacol., 64: 1387-1398 (2002).
39. Rowland, P., Blaney, F. E., Smyth, M. G., Jones, J. J., Leydon, V. R., Oxbrow, A. K., Lewis, C. J., Tennant, M. G., Modi, S., Eggleston, D. S., Chenery, R. J. and Bridges, A. M.: Crystal structure of human cytochrome P450 2D6. J. Biol. Chem., 281: 7614-7622 (2006).
40. Wang, A., Savas, U., Hsu, M. H., Stout, C. D. and Johnson, E. F.: Crystal structure of human cytochrome P450 2D6 with prinomastat bound. J. Biol. Chem., 287: 10834-10843 (2012).
41. Lyne, P. D., Lamb, M. L. and Saeh, J. C.: Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J. Med. Chem., 49: 4805-4808 (2006).
42. Du, J., Sun, H., Xi, L., Li, J., Yang, Y., Liu, H. and Yao, X.: Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MM-GBSA calculation. J. Comput. Chem., 32: 2800-2809 (2011).